Endo International PLC must answer securities fraud claims over alleged misrepresentations concerning the addictive qualities of its reformulated Opana ER opioid product, a federal trial court said Dec. 10.
Endo executives misrepresented that changes to the product deterred its abuse, even though they allegedly knew of studies suggesting the abuse increased after the company released the new version, SEB Investment Management AB claimed in a putative class action filed in the U.S. District Court for the Eastern District of Pennsylvania.
SEB’s claims that Endo and its executives intentionally “downplayed the risks” of the reformulated drug stated a cause of action ...
